Mori, Hirotaka Ohkawara, Hiroshi Togawa, Ryuichi Rikimaru, Mami Shibata, Yoko Ikezoe, Takayuki
Published in
International Journal of Hematology
Background Disseminated intravascular coagulation (DIC) is noted in severe cases of coronavirus disease 2019 (COVID-19). Recently, a number of studies evaluating the diagnosis and treatment of DIC in COVID-19 patients have been reported. Objective The aim of this study is to identify existing gaps where further research is needed on the diagnosis a...
Iba, Toshiaki Connors, Jean Marie Spyropoulos, Alex C. Wada, Hideo Levy, Jerrold H.
Published in
International Journal of Hematology
Thromboembolic events contribute to morbidity and mortality in coronavirus disease 2019 (COVID-19). As a result, thromboprophylaxis using low-molecular-weight heparin (LMWH) is universally recommended for hospitalized patients based on multiple guidelines. However, ethnic differences with respect to thrombogenicity have been reported and the incide...
Kerbikov, Oleg Orekhov, Pavel Borskaya, Ekaterina Nosenko, Natalia
Published in
International Journal of Hematology
Increasing evidence suggests that COVID-19 may be associated with venous thromboembolism, and much data exists regarding high incidence of venous thrombosis in critical COVID-19 patients. However, evidence on this complication in less severe patients is not widely available. The aim of this study was to investigate the incidence of deep-vein thromb...
Izutsu, Koji Ogura, Michinori Tobinai, Kensei Hatake, Kiyohiko Sakamoto, Shigeru Nishimura, Masanori Hoshino, Miyako
Published in
International Journal of Hematology
Brentuximab vedotin (BV) was initially approved in Japan for the treatment of relapsed/refractory (R/R) CD30-positive Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). As requested by the Japanese Ministry of Health, Labour and Welfare, we conducted a post-marketing surveillance (PMS) study to assess the safety of BV in Jap...
Iba, Toshiaki Connors, Jean Marie Nagaoka, Isao Levy, Jerrold H
Published in
International Journal of Hematology
Disseminated intravascular coagulation (DIC) is a common and life-threatening complication in sepsis. Sepsis-associated DIC is recognized as the systemic activation in coagulation with suppressed fibrinolysis that leads to organ dysfunction in combination with systemic intravascular inflammation. In this process, thrombin contributes a key role in ...
Liu, Fuhong Xue, Song Zhang, Yongping Yang, Jingxian Hu, Jiajun Li, Di Ma, Xiaojun Wang, Jingbo
Published in
International Journal of Hematology
In this study, we aimed to improve understanding of the clinical manifestations, laboratory findings, and risk factors of Clostridium perfringens sepsis in patients with acute leukemia and to analyze treatment strategies for improving prognosis. We analyzed clinical manifestations, laboratory data, diagnosis, and treatment strategies in three cases...
Asakura, Hidesaku
Published in
International Journal of Hematology
Asakura, Hidesaku Ogawa, Haruhiko
Published in
International Journal of Hematology
The pathology of coronavirus disease 2019 (COVID-19) is exacerbated by the progression of thrombosis, and disseminated intravascular coagulation (DIC), and cytokine storms. The most frequently reported coagulation/fibrinolytic abnormality in COVID-19 is the increase in d -dimer, and its relationship with prognosis has been discussed. However, limit...
Sanchez, Sandra Veloza, Luis Wang, Luojun López, Mónica López-Guillermo, Armando Marginet, Marta Martínez, Antonio Balagué, Olga Campo, Elias
Published in
International journal of hematology
Human herpesvirus type 8 (HHV8) is a gamma herpesvirus known for its role in lymphoid neoplasms, especially in immunosuppressed patients. We describe the case of a 64-year-old male, without known immunodeficiency, with 1-year-long clinical history of mediastinal and abdominal lymphadenopathies and recurrent pulmonary infections. Histopathological e...
Takezako, Naoki Shibayama, Hirohiko Handa, Hiroshi Hagiwara, Shotaro Ozaki, Shuji Suzuki, Kenshi Kosugi, Hiroshi Ri, Masaki Sugiura, Isamu Choi, Ilseung
...
Published in
International Journal of Hematology
A.R.R.O.W. evaluated the superiority of once-weekly carfilzomib plus dexamethasone (Kd) 20/70 mg/m2 vs. twice-weekly Kd 20/27 mg/m2 based on progression-free survival (PFS) in relapsed and/or refractory multiple myeloma patients. Forty Japanese patients (once-weekly arm, n = 26; twice-weekly arm, n = 14) were randomized in A.R.R.O.W. In the Japanes...
